Title: A Comparative study of Topical Besifloxacin Vs. Moxifloxacin in Management of Bacterial Keratitis
Authors: Dr Subhabrata Parida, Assoc Prof, Dr Satya Ranjan Mallick
DOI: https://dx.doi.org/10.18535/jmscr/v5i7.74
Abstract
This comprehensive review summarises the pharmacokinetics, efficacy, and safety of besifloxacin ophthalmic suspension 0.6% against moxifloxacin 0.3% solution and examines its role in the treatment of ocular surface bacterial infections. Besifloxacin possesses balanced activity against bacterial topoisomerase 2(also called DNA gyrase) and topoisomerase 4. Ocular pharmacokinetic studies have shown that besifloxacin achieves high, sustained concentrations in the tear fluid and conjunctiva following topical administration, with negligible systemic exposure. Large randomized, controlled clinical trials have established the efficacy and safety of besifloxacin administered 3 times daily for 5 days for treatment of acute bacterial conjunctivitis in both adults and children.
In our study, we are trying to compare the efficacy of besifloxacin vs. moxifloxacin topical for simple bacterial keratitis without perforation or any other complication. Patients with other systemic diseases like diabetes, collagen diseases, immunocompromised state or any other infectious disease were excluded from our study. All culture positive acute bacterial keratitis coming to our tertiary institute were selected randomly. Alternatively we treated them with either besifloxacin or moxifloxacin. Then followed them on 3,7,15,30 days respectively, noting all signs, symptoms, slitlamp biomicroscopy, visual acuity, slitlamp photography, patient’s overall satisfaction etc.
We found both the drugs equally effective, but doses frequency less in besifloxacin group, patient reliability and comfort also more in besifloxacin group.
Keywords- Topical, Besifloxacin, Moxifloxacin,Bacterial Keratitis.
References
1. Carter NJ, Scott LJ. Besioxacin ophthalmic suspension 0.6%. Drugs. 2010;70:83-97
2. McDonnell PJ. How do general practitioners manage eye diseases in the community? Br J Ophthalmol. 1988;72:733-6
3. O’brien TP. Besioxacin ophthalmic suspension, 0.6%: a novel topical furoroquinolone for bacterial conjunctivitis. Adv Ther. 2012;29:473-90.
4. Carreras B. Bacteriological analysis in the management of conjunctivitis. Comparison of antibiotic resistance between 1982 and 2008. Arch Soc Exp Oftalmol. 2012;87:107-11
5. Wong RL, Gangwani RA, Yu LW, Lai JS. New treatments for bacterial keratitis. J Ophthalmol. 2012;2012:831502
6. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol. 2004:49(Suppl. 2):S79-83
7. DeLeon J. Silverstein BE, Allaire C, et al. Besioxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children. Clin DrugInvestig. 2012; 32:303-17.
8. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice PatternGuidelines. Bacterial Keratitis. San Francisco, Calif.: American Academy of Ophthalmology; 2013.
9. Schechter BA, Parekh JG, Trattler W. Besioxacin ophthalmic suspension, o.6% in the treatment of bacterial keratitis: a retro-spective surveillance study. J Ocul Pharmacol Ther. 2015;31(2):114-21.